Study of SHR-A1811 for non-small cell lung cancer with HER2 changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old to take part.
- You need to have non-small cell lung cancer that has spread or cannot be removed with surgery.
- Your cancer must have a specific change called HER2 alteration.
- You should be able to take care of yourself (ECOG score of 0-2).
- If you are starting SHR-A1811 now or have already started it, it must be within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new drugs (SHR-A1921 and SHR-A2009) for people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after previous treatments, including antibody-drug conjugate therapy. The goal is to see if these drugs can help control the cancer.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests a new targeted drug (SHR-A1811) combined with an immunotherapy drug (adebelimumab) before surgery for patients with early-stage, resectable lung cancer that has a specific HER2 alteration. The goal is to shrink the tumor and improve outcomes.
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This trial tests two drugs, SHR-A1811 and AK112, for people with advanced non-small cell lung cancer that has HER2 changes. It may help if you have not improved on standard treatment or if you have not yet had treatment.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.